Zhaoke Ophthalmology’s Partner Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia
Zhaoke Ophthalmology Commences Commercialisation of its First Drug with Bimatoprost Timolol Eye Drop (晶贝莹®) Obtaining Marketing Authorization from the National Medical Products Administration
Zhaoke Ophthalmology’s Cyclosporine A (CsA) Ophthalmic Gel Passed the Onsite Regulatory and Clinical Trial Inspections by the NMPA, and the GMP Compliance Inspection by the Guangdong Medical Products Administration
